IOL Chemicals & Pharmaceuticals (IOLCP) posted solid Q3 FY26 results. 💪 Revenue grew 10.9% YoY to ₹580.4 Cr, with Profit Before Tax (PBT) surging 39.3% to ₹38.8 Cr.

EBITDA increased 22.8% to ₹62.6 Cr.

The Pharmaceuticals segment showed strong performance, contributing significantly to 9-month revenue.

Strategy focuses on diversifying beyond Ibuprofen, with non-Ibuprofen APIs now making up 34% of pharma revenue.

Key products like Paracetamol, Metformin, and Clopidogrel are driving this shift.

Backward integration is key to securing supply & managing costs.

Recently, the new Unit 11 for Paracetamol (10,800 MTPA capacity) commenced operations, and Clopidogrel capacity was enhanced.

A new UK subsidiary, IOL Pharmaxis UK, was incorporated.

Financially strong, IOLCP boasts a very low Debt-to-Equity ratio of 0.07. Management aims to boost export revenue to ~40% and has acquired 101 acres for future expansion.

R&D pipeline features 9 new products. 📈 #IOLCP #PharmaStocks #API